Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
Rana R. McKay(University of California San Diego), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School), Rupal S. Bhatt(Dana-Farber Cancer Institute), Lillian Werner(Dana-Farber Cancer Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Lucia Kwak(Harvard University), Xiao X. Wei(Dana-Farber Cancer Institute), Glenn J. Bubley(Sidney Kimmel Comprehensive Cancer Center), Bruce Montgomery(Fred Hutch Cancer Center), Rosina T. Lis(Dana-Farber Cancer Institute), Jamie M. Sperger(University of Wisconsin–Madison), Wanling Xie(Dana-Farber Cancer Institute), Peter S. Nelson(Fred Hutch Cancer Center), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Evan Y. Yu(University of Washington), Joshua M. Lang(University of Wisconsin–Madison), Zhenwei Zhang(Shenyang Pharmaceutical University), Jett Crowdis(Broad Institute)
Cited by 32
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k